Stryker BMP Putty Receives HDE Approval For Spine Applications
This article was originally published in The Gray Sheet
Executive Summary
Stryker will extend its OP-1 bone morphogenic protein into the revision spine surgery market following recent humanitarian device exemption clearance of a putty form, the firm announced April 8
You may also be interested in...
Stryker Spine Putty Approval “Significantly” Delayed, Firm Says
FDA is requesting additional data to support Stryker's OP-1 Putty PMA, which could delay approval of the posterolateral lumbar spine fusion surgery indication until 2009, the firm says
Stryker Spine Putty Approval “Significantly” Delayed, Firm Says
FDA is requesting additional data to support Stryker's OP-1 Putty PMA, which could delay approval of the posterolateral lumbar spine fusion surgery indication until 2009, the firm says
Stryker Bets On OP-1 Putty After Encountering A Tough Orthopedic Climate
Stryker says that its OP-1 Putty bone morphogenetic protein will sustain growth levels as its hips and knee products encounter an increasingly challenging pricing environment